Cargando…

OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC

Metabolism plays a critical role in cancer. OLR1 has been implicated in cardiovascular and metabolic disorders, while its association with tumorigenesis and tumor immunity remains poorly defined in the literature. We conducted comprehensive pan-cancer analyses based on the TCGA database to examine O...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lei, Liu, Yuantong, Deng, Weiwei, Wu, Tianfu, Bu, Linlin, Chen, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454104/
https://www.ncbi.nlm.nih.gov/pubmed/37629087
http://dx.doi.org/10.3390/ijms241612904
_version_ 1785096107166007296
author Wu, Lei
Liu, Yuantong
Deng, Weiwei
Wu, Tianfu
Bu, Linlin
Chen, Lei
author_facet Wu, Lei
Liu, Yuantong
Deng, Weiwei
Wu, Tianfu
Bu, Linlin
Chen, Lei
author_sort Wu, Lei
collection PubMed
description Metabolism plays a critical role in cancer. OLR1 has been implicated in cardiovascular and metabolic disorders, while its association with tumorigenesis and tumor immunity remains poorly defined in the literature. We conducted comprehensive pan-cancer analyses based on the TCGA database to examine OLR1 expression and its prognostic implications. Correlations between OLR1 expression level and tumor immunity and immunotherapy were investigated by immune infiltration, enrichment, and TIDE analysis methods. Immunohistochemistry detected OLR1 expression in HNSCC. We used the GSEA method to explore the potential signaling pathways in which OLR1 is involved, and a correlation analysis to investigate the relationships between OLR1 and epithelial–mesenchymal transition (EMT) and cuproptosis. In addition, the effects of OLR1 knockdown on the EMT process, invasion, stemness, and cuproptosis of HNSCC cells were examined by scratch, Transwell, CCK8, sphere formation, and flow cytometry, while changes in related proteins were detected using the immunoblotting method. OLR1 is highly expressed in most cancers, and it is associated with patient prognosis. OLR1 expression positively correlates with immunosuppressive cell infiltration and immune checkpoint molecules, while being negatively associated with effector T cells. Moreover, significant correlations are observed between OLR1 expression and tumor mutation burden (TMB) and microsatellite instability (MSI) in some cancers. In HNSCC, OLR1 expression is related to advanced clinicopathological factors and unfavorable outcomes. Patients with high OLR1 expression levels are prone to experience immune escape and benefit less from immune checkpoint inhibitor (ICI) therapy. Moreover, OLR1 expression may affect EMT, stemness, and cuproptosis resistance outcomes. OLR1 is an immune-related prognostic biomarker with potential as a prognostic indicator for immunotherapy, and it may also be involved in regulating the EMT process and cuproptosis in HNSCC.
format Online
Article
Text
id pubmed-10454104
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104541042023-08-26 OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC Wu, Lei Liu, Yuantong Deng, Weiwei Wu, Tianfu Bu, Linlin Chen, Lei Int J Mol Sci Article Metabolism plays a critical role in cancer. OLR1 has been implicated in cardiovascular and metabolic disorders, while its association with tumorigenesis and tumor immunity remains poorly defined in the literature. We conducted comprehensive pan-cancer analyses based on the TCGA database to examine OLR1 expression and its prognostic implications. Correlations between OLR1 expression level and tumor immunity and immunotherapy were investigated by immune infiltration, enrichment, and TIDE analysis methods. Immunohistochemistry detected OLR1 expression in HNSCC. We used the GSEA method to explore the potential signaling pathways in which OLR1 is involved, and a correlation analysis to investigate the relationships between OLR1 and epithelial–mesenchymal transition (EMT) and cuproptosis. In addition, the effects of OLR1 knockdown on the EMT process, invasion, stemness, and cuproptosis of HNSCC cells were examined by scratch, Transwell, CCK8, sphere formation, and flow cytometry, while changes in related proteins were detected using the immunoblotting method. OLR1 is highly expressed in most cancers, and it is associated with patient prognosis. OLR1 expression positively correlates with immunosuppressive cell infiltration and immune checkpoint molecules, while being negatively associated with effector T cells. Moreover, significant correlations are observed between OLR1 expression and tumor mutation burden (TMB) and microsatellite instability (MSI) in some cancers. In HNSCC, OLR1 expression is related to advanced clinicopathological factors and unfavorable outcomes. Patients with high OLR1 expression levels are prone to experience immune escape and benefit less from immune checkpoint inhibitor (ICI) therapy. Moreover, OLR1 expression may affect EMT, stemness, and cuproptosis resistance outcomes. OLR1 is an immune-related prognostic biomarker with potential as a prognostic indicator for immunotherapy, and it may also be involved in regulating the EMT process and cuproptosis in HNSCC. MDPI 2023-08-17 /pmc/articles/PMC10454104/ /pubmed/37629087 http://dx.doi.org/10.3390/ijms241612904 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Lei
Liu, Yuantong
Deng, Weiwei
Wu, Tianfu
Bu, Linlin
Chen, Lei
OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC
title OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC
title_full OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC
title_fullStr OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC
title_full_unstemmed OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC
title_short OLR1 Is a Pan-Cancer Prognostic and Immunotherapeutic Predictor Associated with EMT and Cuproptosis in HNSCC
title_sort olr1 is a pan-cancer prognostic and immunotherapeutic predictor associated with emt and cuproptosis in hnscc
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454104/
https://www.ncbi.nlm.nih.gov/pubmed/37629087
http://dx.doi.org/10.3390/ijms241612904
work_keys_str_mv AT wulei olr1isapancancerprognosticandimmunotherapeuticpredictorassociatedwithemtandcuproptosisinhnscc
AT liuyuantong olr1isapancancerprognosticandimmunotherapeuticpredictorassociatedwithemtandcuproptosisinhnscc
AT dengweiwei olr1isapancancerprognosticandimmunotherapeuticpredictorassociatedwithemtandcuproptosisinhnscc
AT wutianfu olr1isapancancerprognosticandimmunotherapeuticpredictorassociatedwithemtandcuproptosisinhnscc
AT bulinlin olr1isapancancerprognosticandimmunotherapeuticpredictorassociatedwithemtandcuproptosisinhnscc
AT chenlei olr1isapancancerprognosticandimmunotherapeuticpredictorassociatedwithemtandcuproptosisinhnscc